AstraZeneca patent revoked for obviousness

No items found.
​
March 29, 2012

In a decision on 22 March in Teva and ors v AstraZeneca concerning a patent on a sustained release formulation of an anti-psychotic drug, Mr Justice Arnold revoked the patent due to obviousness.

In his IPKat blog, Darren Smyth draws comparisons between this decision and that of Actavis v Novartis, which involved a patent concerning a sustained release formulation of fluvastatin that was held to be obvious.

Recent Case Reports

Qualified electronic signatures not necessary at the UPC after all
17 November 2026
The UPC Court of Appeal confirmed that a scanned handwritten signature satisfies R. 4.1 RoP, and that a qualified or advanced electronic signature is not required. It also upheld the Brussels Local Division's decision to keep Dutch as the language of proceedings, as all parties are Flemish-based and the claimant is a small enterprise.
Milan Local Division: formal and sequential evaluation of infringement notice under FRAND
17 November 2026
The Milan Local Division held that an SEP holder with a dominant position must, before commencing an action seeking an injunction, identify the asserted patent and explain how it is allegedly infringed sufficiently early to permit a genuine response. Notice given on the filing date, could not cure the omission, and this was not altered by the fact the injunction request was conditional.
Invalidity of juicer patent upheld on appeal
03 November 2026
The Court of Appeal upheld the invalidity of Hurom’s juicer patent for lack of inventive step, while clarifying the admissibility requirements for patent amendments and the use of the unamended description when construing amended claims. It also confirmed the UPC’s jurisdiction over infringement in Poland despite Poland not being a UPCA Contracting Member State, but found that Hurom had failed to establish infringement under Polish law.